Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.
about
ChannelopathiesRapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodiesGlutamatergic autoencephalitides: an emerging fieldCaV channels and cancer: canonical functions indicate benefits of repurposed drugs as cancer therapeuticsPyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibodyGuidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Autoimmune encephalopathies.Therapeutic plasma exchange in neurology: 2012.Synthesis and biological evaluation of a selective N- and p/q-type calcium channel agonist.Lambert-Eaton Myasthenic Syndrome with A Twenty-Three-Year Delay in Diagnosis.Paraneoplastic syndromes associated with lung cancerSynaptotagmin 2 mutations cause an autosomal-dominant form of lambert-eaton myasthenic syndrome and nonprogressive motor neuropathySynaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.Functional Connectivity under Optogenetic Control Allows Modeling of Human Neuromuscular Disease.Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort studyRegulation of neurovascular coupling in autoimmunity to water and ion channelsAutoimmune encephalopathy and drug refractory seizures with the presence of two autoantibodies specific for the neuronal cell surface.Lambert-Eaton syndrome IgG inhibits transmitter release via P/Q Ca2+ channels.Voltage gated calcium channel antibody-related neurological diseasesComplete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist.Paraneoplastic disordersMediastinal small cell cancer associated with Lambert-Eaton myasthenic syndrome: A case reportAvoiding misdiagnosis in patients with neurological emergencies.Sympathetic innervation controls homeostasis of neuromuscular junctions in health and disease.Successful treatment of Lambert-Eaton myasthenic syndrome in a small cell lung cancer patient using 3,4-diaminopyridine: A case reportEvaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndromeNeuronal autoantigens--pathogenesis, associated disorders and antibody testingThe association between Lambert-Eaton myasthenic syndrome and small cell lung carcinomaPseudomyopathic changes in needle electromyography in lambert-eaton myasthenic syndrome.SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma.Treatment in Lambert-Eaton myasthenic syndrome.Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management.Paraneoplastic immune-mediated neurological effects of systemic cancers.Paraneoplastic disorders in thymoma patients.Triads in Ophthalmology: A Comprehensive Review.Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton MyastheniaReview of the Diagnostic Challenges of Lambert-Eaton Syndrome Revealed Through Three Case Reports.Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System.Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.Subacute Cerebellar Degeneration due to a Paraneoplastic Phenomenon Associated with Metastatic Merkel Cell Carcinoma: A Case Report.
P2860
Q24601791-171C3279-D81E-4AE5-B0E2-4D517E26E6BBQ26864907-89FBA12A-741E-499B-BF10-3D8E1C2A2B62Q26992294-ADC3EB37-644B-42A2-B7E1-3D3B84E5940EQ28078594-ADB831DA-AED0-4BA7-AAB8-1AA36119EE21Q28286248-FF7033F4-BB1D-4DE1-9D1A-2BFE575ADD5CQ30276550-1656DA38-D85E-4C58-B3B6-1F95EC242E9BQ30389491-DDC11108-577C-4843-BD34-2E4EFD7D60BDQ30415046-1ACDB90F-881C-4D88-9F73-4133F54FFA99Q33752856-DB2B3F9F-5F77-4B6A-9BDB-150434C85CCFQ33854926-F248EB02-BAC0-4E5E-95F4-3CA7A7D51CCDQ34023610-EC6A0A78-D9E2-4D38-AD23-AB90EB0CBA2EQ34146828-DAC470D4-2890-45F5-902B-8E1A567D6120Q34437216-5520DCAA-9737-41BE-B737-C92947F10099Q34501054-8BB91106-627C-4078-BE3C-56F49A2D383AQ34548870-508188E1-FABC-4D58-8456-DCD12832C955Q35001946-155B5FE2-94F2-43C5-89FF-A99BD2D526EAQ35018526-A4128E30-8E91-4868-A22E-C120D496F954Q35106229-EE0AB903-BABE-4243-A8E6-486513D4C66CQ35179343-3ADB257F-3345-4E32-ADCF-967C02532D8FQ35205835-A93FBD39-3720-4019-BCED-42197421A5F5Q35646721-54642024-25A6-4865-8496-864287FE6C4DQ35802705-31FA7FE1-59A2-44B3-83F0-934600EFD7D4Q36134962-F10EF01F-37E9-462C-BFB0-141353AB204FQ36498367-34002114-1496-4D6A-815F-A5330DDAF3A4Q36640458-2CAE4B7F-3723-4824-AF7A-82CDC76CD436Q36938303-A9A77F12-4078-4F15-AE2C-84ACC7506B41Q37032830-4E598EE9-E213-4759-BAED-7C44443AB7B7Q37054967-4551F332-16DA-44F6-AA19-4C48C8725A1CQ37067722-5700D007-5DA8-48D6-8FD9-E98EC6BCCAC1Q38070757-A661C3B1-0880-415A-BBAF-1B1136C61D52Q38070758-BC9FF916-BA53-4852-83EA-CF53B0714FC1Q38183705-917259F0-D78A-46AE-829B-3C0BA203BC4DQ38199135-008C7418-E164-4CAF-8437-84CCF6F56653Q38268144-B1FBDC3F-01F5-4C79-A060-CC851885ED9CQ38543193-ECE123B5-A4AA-4E60-8E3F-CA1C9C3A40E9Q38721390-35256D1E-24BF-4DD9-BEEA-BA53AC6D03CEQ38895764-642681A7-3A29-4470-96FE-92EA9D5B8D1EQ39180685-95667937-7F20-404D-B1EB-294209AB76D3Q39368677-01FF8795-8560-4C54-B8F7-970FA066C3E6Q41601609-66F62C82-10B6-4E26-845A-553A6144C785
P2860
Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Lambert-Eaton myasthenic syndr ...... ics to therapeutic strategies.
@ast
Lambert-Eaton myasthenic syndr ...... ics to therapeutic strategies.
@en
Lambert-Eaton myasthenic syndr ...... ics to therapeutic strategies.
@nl
type
label
Lambert-Eaton myasthenic syndr ...... ics to therapeutic strategies.
@ast
Lambert-Eaton myasthenic syndr ...... ics to therapeutic strategies.
@en
Lambert-Eaton myasthenic syndr ...... ics to therapeutic strategies.
@nl
prefLabel
Lambert-Eaton myasthenic syndr ...... ics to therapeutic strategies.
@ast
Lambert-Eaton myasthenic syndr ...... ics to therapeutic strategies.
@en
Lambert-Eaton myasthenic syndr ...... ics to therapeutic strategies.
@nl
P1433
P1476
Lambert-Eaton myasthenic syndr ...... tics to therapeutic strategies
@en
P2093
Bethan Lang
P304
P356
10.1016/S1474-4422(11)70245-9
P577
2011-12-01T00:00:00Z